HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Correspondence: Submit a response Correspondence: View responses Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cohen, B. A. Articles by Mikol, D. D. Search for Related Content PubMed PubMed Citation Articles by Cohen, B. A. Articles by Mikol, D. D.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Mitoxantrone treatment of multiple sclerosis

Safety considerations

From the Davee Department of Neurology, Northwestern University, Chicago, Illinois (Dr. Cohen) and the Department of Neurology, University of Michigan, Ann Arbor, Michigan (Dr. Mikol).

Address correspondence and reprint requests to Dr. Bruce A. Cohen, Northwestern University Department of Neurology, 710 North Lake Shore Drive, Abbott Hall 1121, Chicago, IL 60611; e-mail: bac106{at}northwestern.edu

Treatment of patients with mitoxantrone for worsening multiple sclerosis (MS) requires careful monitoring for possible adverse events. Common side effects that are minor and easily managed include transient leukopenia and elevated liver enzymes, nausea, alopecia, bluish discoloration of urine, and urinary tract infections. Amenorrhea, severe infection, cardiac toxicity, and toxic leukemias are more serious adverse events associated with mitoxantrone treatment but occur infrequently. The potential for clinically significant heart failure is low and is dose-related. Subclinical reductions in left ventricular ejection fraction may occur with serial doses, underscoring the importance of careful monitoring before initiating and during treatment. The risk for chronic cardiomyopathy limits the approved cumulative dose of mitoxantrone for treatment of MS to 140 mg/m². Dexrazoxane has a cardioprotective effect when used with anthracycline in the treatment of patients with neoplasms. Studies under way address whether concomitant administration of dexrazoxane with mitoxantrone might decrease the risk for cardiac toxicity in MS patients and perhaps increase the allowable cumulative dose of mitoxantrone. A phase IV clinical study of mitoxantrone (RENEW) is in progress to assess the long-term safety and tolerability of treatment. Careful laboratory and cardiac monitoring can reduce the possibility of adverse events and enhance patient safety.

This article has been cited by other articles:

				S. Cotte, N. von Ahsen, N. Kruse, B. Huber, A. Winkelmann, U. K. Zettl, M. Starck, N. Konig, N. Tellez, J. Dorr, et al. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis Brain, September 1, 2009; 132(9): 2517 - 2530. [Abstract] [Full Text] [PDF]

				F Paul, J Dorr, J Wurfel, H-P Vogel, and F Zipp Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis BMJ Case Reports, July 7, 2009; 2009(jul07_1): bcr0620092004 - bcr0620092004. [Abstract] [Full Text]

				S. A. Sadiq, M. Rammal, and G. Sara Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS Multiple Sclerosis, March 1, 2008; 14(2): 272 - 273. [Abstract] [PDF]

				F. Ubiali, S. Nava, V. Nessi, R. Longhi, G. Pezzoni, R. Capobianco, R. Mantegazza, C. Antozzi, and F. Baggi Pixantrone (BBR2778) Reduces the Severity of Experimental Autoimmune Myasthenia Gravis in Lewis Rats J. Immunol., February 15, 2008; 180(4): 2696 - 2703. [Abstract] [Full Text] [PDF]

				F Paul, J Dorr, J Wurfel, H-P Vogel, and F Zipp Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis J. Neurol. Neurosurg. Psychiatry, February 1, 2007; 78(2): 198 - 200. [Full Text] [PDF]

				I. Tuin, U. Voss, J. -S. Kang, K. Kessler, U. Rub, D. Nolte, H. Lochmuller, S. Tinschert, D. Claus, K. Krakow, et al. Stages of sleep pathology in spinocerebellar ataxia type 2 (SCA2) Neurology, December 12, 2006; 67(11): 1966 - 1972. [Abstract] [Full Text] [PDF]

				D. E. Gladstone, K. W. Zamkoff, L. Krupp, R. Peyster, P. Sibony, C. Christodoulou, E. Locher, and P. K. Coyle High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis Arch Neurol, October 1, 2006; 63(10): 1388 - 1393. [Abstract] [Full Text] [PDF]

				A. S. Paintlia, M. K. Paintlia, I. Singh, and A. K. Singh Immunomodulatory Effect of Combination Therapy with Lovastatin and 5-Aminoimidazole-4-Carboxamide-1-{beta}-D-Ribofuranoside Alleviates Neurodegeneration in Experimental Autoimmune Encephalomyelitis Am. J. Pathol., September 1, 2006; 169(3): 1012 - 1025. [Abstract] [Full Text] [PDF]

				M. A. Friese, X. Montalban, N. Willcox, J. I. Bell, R. Martin, and L. Fugger The value of animal models for drug development in multiple sclerosis Brain, August 1, 2006; 129(8): 1940 - 1952. [Abstract] [Full Text] [PDF]

				R. G. Pratt, G. A. Boehm, C. M. Kortepeter, J. A. Racoosin, B. A. Cohen, and D. D. Mikol Mitoxantrone treatment of multiple sclerosis: Safety considerations Neurology, December 27, 2005; 65(12): 1997 - 1997. [Full Text] [PDF]

				B R Thanvi, T C N Lo, and D P Harsh Psychosis in Parkinson's disease Postgrad. Med. J., October 1, 2005; 81(960): 644 - 646. [Abstract] [Full Text] [PDF]

Correspondence: